Neuro-Immune Crosstalk in Rheumatoid Arthritis: The Bidirectional Path of Pain and Cytokines

Overview

The traditional conceptualisation of Rheumatoid Arthritis (RA) as a localised, peripheral inflammatory arthropathy is increasingly viewed as a reductionist relic in the face of contemporary neuroimmunological evidence. At INNERSTANDIN, our interrogation of the latest clinical data reveals that RA is more accurately defined as a systemic dysregulation of the neuro-immune axis. This bidirectional pathway facilitates a relentless dialogue between the central nervous system (CNS) and the peripheral immune apparatus, where proinflammatory cytokines and neural signals reinforce a state of chronic pathological tension. This overview delineates the mechanistic nexus through which synovial inflammation transcends the joint capsule to recalibrate the neurological landscape, and conversely, how the nervous system actively modulates the inflammatory cascade.

The fundamental architecture of this crosstalk is built upon the migration of cytokines—most notably tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and IL-1β—from the inflamed synovium into systemic circulation. These molecules breach the blood-brain barrier (BBB) via saturated transport systems or through the circumventricular organs where the barrier is physiologically compromised. Once within the CNS, these cytokines trigger microglial activation, transitioning these resident macrophages into a pro-inflammatory M1 phenotype. This process, as documented in studies published in *The Lancet Rheumatology*, results in "central sensitisation," a state where the CNS amplifies sensory input, leading to hyperalgesia and allodynia that often persist even when clinical remission of joint swelling is achieved via conventional DMARD (Disease-Modifying Antirheumatic Drug) therapy.

Simultaneously, the peripheral nervous system acts as a conduit for "neurogenic inflammation." Nociceptors within the joint do not merely signal pain; they actively participate in the pathology by releasing neuropeptides such as Substance P and Calcitonin Gene-Related Peptide (CGRP). These molecules facilitate vasodilation, increase vascular permeability, and recruit further leucocytes to the site of injury, creating a feedback loop that sustains synovial destruction. Research highlighted in the *British Journal of Pharmacology* underscores how this efferent neural activity directly influences the severity of bone erosions and cartilage loss, suggesting that the "pain" of RA is a primary driver of the "inflammation" rather than a mere secondary symptom.

Furthermore, the autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal (HPA) axis are pivotal in this systemic imbalance. In the UK, where RA affects approximately 1% of the population, clinical observations frequently note a high prevalence of comorbid fatigue, depression, and cognitive dysfunction—symptoms collectively known as "sickness behaviour." This is not an emotional response to illness, but a direct biological consequence of cytokine-induced neuro-inflammation. The cholinergic anti-inflammatory pathway, primarily mediated by the vagus nerve, is often found to be hypoactive in RA patients, failing to exert its requisite inhibitory control over cytokine production by splenic macrophages. At INNERSTANDIN, we assert that understanding this bidirectional path is essential for moving beyond "symptom management" toward a holistic biological resolution. The neuro-immune crosstalk is not merely a feature of RA; it is the engine of its chronicity.

The Biology — How It Works

The pathogenesis of Rheumatoid Arthritis (RA) has historically been reduced to a localized autoimmune failure within the synovial compartment. However, a deeper INNERSTANDIN of the disease architecture reveals a sophisticated, bidirectional communication network between the central nervous system (CNS) and the immune apparatus—a phenomenon known as neuro-immune crosstalk. This is not merely a secondary symptom of joint degradation but a primary driver of disease chronicity and systemic morbidity. At the heart of this biology lies the synovial-neuro interface, where high-density nociceptive afferents (specifically Aδ and C fibres) do not merely transmit pain signals but actively modulate the inflammatory milieu through the release of neuropeptides.

When the synovial membrane is infiltrated by leucocytes, the resulting "cytokine storm"—dominated by Tumour Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and IL-1β—lowers the activation threshold of peripheral nociceptors. This peripheral sensitisation is facilitated by the upregulation of transient receptor potential (TRP) channels, such as TRPV1 and TRPA1, on sensory neurons. Once activated, these neurons undergo "antidromic signalling," releasing Substance P and Calcitonin Gene-Related Peptide (CGRP) directly into the joint space. These neuropeptides are potent vasodilators and chemoattractants; they increase vascular permeability and stimulate synoviocytes and macrophages to secrete further pro-inflammatory cytokines, creating a self-perpetuating loop termed neurogenic inflammation.

The communication, however, is not unidirectional. Peripheral cytokines gain entry to the CNS via leaky regions of the blood-brain barrier (the circumventricular organs) or through active transport mechanisms. Research published in *The Lancet Rheumatology* and *Nature Reviews Immunology* highlights that once these signals reach the brain, they trigger microglial activation. These resident immune cells of the CNS transition from a quiescent to a phagocytic phenotype, releasing their own battery of neuro-inflammatory mediators. This process leads to central sensitisation—a rewiring of the dorsal horn of the spinal cord and higher cortical centres—which explains why RA patients often experience "pain-memory" and hyperalgesia even when clinical markers of peripheral inflammation, such as C-Reactive Protein (CRP), appear controlled.

Furthermore, the "Inflammatory Reflex," primarily mediated by the vagus nerve, represents the body's attempt at systemic regulation. In a healthy state, the efferent vagal pathway releases acetylcholine, which binds to α7 nicotinic acetylcholine receptors (α7nAChR) on macrophages, inhibiting TNF-α production. In the RA phenotype, this cholinergic anti-inflammatory pathway is frequently compromised. This autonomic dysregulation, coupled with a blunted Hypothalamic-Pituitary-Adrenal (HPA) axis—where cortisol production fails to scale with the degree of systemic inflammation—leaves the immune system "unbraked." At INNERSTANDIN, we posit that the "biology" of RA is as much a neurological dysfunction as it is an immunological one; the persistence of the disease is a failure of these two systems to reach a homeostatic truce, resulting in the systemic erosion of biological integrity.

Mechanisms at the Cellular Level

The pathogenesis of Rheumatoid Arthritis (RA) is no longer confined to the sequestered remit of classical immunology; at the cellular level, it represents a sophisticated, bidirectional dialogue between the peripheral nervous system and the innate and adaptive immune complexes. This neuro-immune synapse, established within the inflamed synovium, operates through a mechanism termed 'neurogenic inflammation.' Primary afferent nociceptors, particularly unmyelinated C-fibres and lightly myelinated Aδ-fibres, do not merely act as passive conduits for pain stimuli. Instead, they function as active immunomodulators. Upon activation by pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6—ubiquitous in the RA microenvironment—these neurons undergo depolarisation that triggers the antidromic release of neuropeptides, specifically Substance P (SP) and Calcitonin Gene-Related Peptide (CGRP).

Research published in *The Lancet Rheumatology* and archives from *Nature Reviews Rheumatology* highlights that SP and CGRP directly interface with synovial fibroblasts (FLS) and resident macrophages. SP, via the Neurokinin-1 receptor (NK1R), induces the upregulation of adhesion molecules and the secretion of further proinflammatory mediators, creating a self-perpetuating feedback loop that exacerbates synovial hyperplasia and pannus formation. Concurrently, CGRP facilitates potent vasodilation, increasing vascular permeability and the subsequent extravasation of leucocytes into the articular space. This is a critical realization at INNERSTANDIN: the nervous system is not reacting to the disease; it is an architectural driver of the inflammatory milieu.

The cellular crosstalk is further refined by the expression of cytokine receptors directly on the nociceptor terminals. TNF-α binds to TNFR1, initiating a phosphorylation cascade involving mitogen-activated protein kinases (MAPK) and protein kinase C (PKC). This intracellular signalling lowers the activation threshold of voltage-gated sodium channels, notably Nav1.7 and Nav1.8, and the transient receptor potential vanilloid 1 (TRPV1) channels. This molecular 'priming' results in peripheral sensitisation, where previously innocuous mechanical pressures (allodynia) are perceived as noxious.

Furthermore, the dialogue extends beyond the peripheral joint to the dorsal horn of the spinal cord. Here, the 'tripartite synapse' involving neurons, microglia, and astrocytes becomes the focal point of central sensitisation. Chronically activated by peripheral input, microglia release Brain-Derived Neurotrophic Factor (BDNF) and IL-18, which further amplify excitatory synaptic transmission. Evidence from King’s College London neuro-immunology units suggests that this spinal glial activation is a primary reason why RA patients often experience persistent pain despite achieving clinical remission (low DAS28 scores).

Crucially, the 'Cholinergic Anti-inflammatory Pathway' (CAP), mediated via the vagus nerve, serves as the systemic counter-regulatory mechanism. Acetylcholine (ACh) released by efferent vagal fibres interacts with the alpha-7 nicotinic acetylcholine receptor (α7nAChR) on macrophages. This interaction inhibits the translocation of NF-κB to the nucleus, effectively suppressing the production of TNF-α. At INNERSTANDIN, we expose the reality that RA is a failure of this neuro-immune homeostasis, where the proinflammatory 'threat' signal from the nociceptor overrides the vagal 'calm' signal, resulting in the systemic cytokine storms characteristic of the disease. This cellular interface defines the true frontier of RA therapeutics.

Environmental Threats and Biological Disruptors

The pathogenesis of Rheumatoid Arthritis (RA) cannot be decoupled from the external milieu; the environment acts as a potent epigenetic rheostat, modulating the bidirectional signaling between the central nervous system (CNS) and the immune architecture. At INNERSTANDIN, we recognise that the modern landscape is saturated with biological disruptors that bypass traditional physiological barriers to incite systemic neuro-inflammation. Central to this disruption is the inhalation of particulate matter (PM2.5) and nitrogen dioxide—major constituents of UK urban air pollution—which initiates a "lung-joint axis" of inflammation. Evidence published in *The Lancet Rheumatology* suggests that these particulates do not merely cause pulmonary stress; they trigger the citrullination of proteins within alveolar macrophages. This post-translational modification serves as the primary neoantigenic stimulus for anti-citrullinated protein antibodies (ACPAs), the hallmark of erosive RA.

Crucially, this environmental insult is transduced via the vagus nerve and the HPA axis, illustrating the "sensory" role of the immune system. When the lungs are exposed to xenobiotics or tobacco smoke—the latter being the most significant environmental risk factor in the UK population—pro-inflammatory cytokines such as TNF-α and IL-6 enter the systemic circulation. These cytokines are not merely inflammatory markers; they are neuroactive molecules. They penetrate the blood-brain barrier at the circumventricular organs or signal through the afferent vagus nerve, inducing a state of "sickness behaviour" and central sensitisation. This neuro-immune crosstalk ensures that environmental threats are translated into a heightened state of nociception. Substance P and Calcitonin Gene-Related Peptide (CGRP) are subsequently released from peripheral nerve endings in the synovium, directly stimulating synoviocytes to produce more IL-6, creating a self-perpetuating feedback loop of neurogenic inflammation.

Furthermore, the modern UK environment imposes a chronobiological threat through circadian rhythm disruption and "blue light" toxicity. Research highlighted in *Nature Reviews Rheumatology* indicates that the molecular clock within leucocytes and synovial fibroblasts is intricately linked to the HPA axis’s diurnal cortisol rhythm. In a state of environmental dyssynchrony, the nocturnal surge of pro-inflammatory cytokines—specifically IL-12 and melatonin’s pro-inflammatory effects—goes unchecked by cortisol, leading to the characteristic morning stiffness and excruciating pain experienced by RA patients. This is not a failure of the joints, but a failure of the neuro-immune synchronisation required to suppress inflammatory peaks.

Finally, the disruption of the gut-brain-joint axis via ultra-processed diets and the prophylactic overuse of antibiotics in the UK has led to widespread dysbiosis. The loss of *Prevotella copri* homeostasis and the subsequent increase in intestinal permeability (the "leaky gut" phenomenon) allows for the translocation of bacterial lipopolysaccharides (LPS) into the portal circulation. This endotoxaemia acts as a persistent biological disruptor, priming microglial cells within the CNS and lowering the threshold for pain perception. At INNERSTANDIN, we assert that RA is the symptomatic manifestation of an organism losing its ability to distinguish between environmental signals and biological threats, resulting in a systemic neuro-immune collapse.

The Cascade: From Exposure to Disease

The transition from asymptomatic autoimmunity to clinically apparent Rheumatoid Arthritis (RA) represents a multisystemic failure of homeostatic regulation, characterised by a transition from mucosal-site initiation to systemic synovial targeting. This cascade typically begins at the interface of environmental triggers—such as pulmonary insults from tobacco smoke or the dysbiotic influence of *Porphyromonas gingivalis* in the oral cavity—and a high-risk genetic background, most notably the HLA-DRB1 ‘shared epitope’ alleles. At these mucosal sites, the post-translational modification of proteins, specifically citrullination, serves as the primary antigenic stimulus. The resulting loss of immunological self-tolerance leads to the generation of anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF), which often circulate in the serum of UK patients for years before the transition to inflammatory synovitis.

Crucial to the INNERSTANDIN model of disease progression is the recognition that the transition to symptomatic RA is governed by a bidirectional neuro-immune interface. As ACPAs and pro-inflammatory cytokines, such as Tumour Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and IL-1β, begin to populate the synovial fluid, they do more than merely recruit leucocytes; they act as potent ligands for the peripheral nervous system. Sensory nociceptors, particularly peptidergic C-fibres and Aδ-fibres, express an array of cytokine receptors (e.g., TNFR1 and IL-6R). Upon binding, these receptors initiate intracellular signalling pathways that lower the threshold for action potential generation—a process known as peripheral sensitisation.

However, the cascade is not a one-way street from immune cell to neuron. The sensory nerves themselves are active participants in the inflammatory milieu. When activated, these afferent fibres undergo antidromic conduction, leading to the peripheral release of neuropeptides, including Substance P and Calcitonin Gene-Related Peptide (CGRP). These neuropeptides are not merely neurotransmitters; they are potent modulators of vascular and immune function. CGRP induces potent vasodilation, while Substance P increases vascular permeability and stimulates synovial fibroblasts to produce further IL-6 and matrix metalloproteinases (MMPs), which facilitate the degradation of the articular cartilage. This neurogenic inflammation acts as a feed-forward loop, exacerbating the recruitment of macrophages and T-lymphocytes (specifically Th17 cells) to the joint space.

Furthermore, research increasingly demonstrates that the cascade extends into the Central Nervous System (CNS) through the humoral and neural pathways. Systemic cytokines can bypass the blood-brain barrier via the circumventricular organs or through active transport, while the vagus nerve provides a high-speed conduit for peripheral inflammatory signals to reach the nucleus tractus solitarius. Once the CNS is involved, the 'disease cascade' shifts toward central sensitisation. This is the physiological basis for the chronic pain and fatigue frequently observed in clinical settings across the UK, where patients report severe pain intensity that often appears disproportional to the degree of visible joint swelling. Within this neuro-immune framework, the cascade is viewed not as a localised joint disease, but as a systemic breakdown where the nervous system both responds to and drives the progressive destruction of the synovial architecture.

What the Mainstream Narrative Omits

The conventional clinical paradigm predominantly frames Rheumatoid Arthritis (RA) as a localised, synovial-centric autoimmune pathology, where the neurological component—specifically pain—is relegated to a secondary, symptomatic consequence of tissue degradation. At INNERSTANDIN, we recognise this as a reductive oversimplification that ignores the profound bidirectional regulatory circuitry known as the neuro-immune axis. The mainstream narrative largely neglects the role of neurogenic inflammation, a process wherein peripheral nociceptors do not merely transmit pain signals to the dorsal horn but actively secrete pro-inflammatory neuropeptides, such as Substance P (SP) and Calcitonin Gene-Related Peptide (CGRP), directly into the joint microenvironment. These neuropeptides facilitate vasodilation and increased vascular permeability, thereby augmenting the recruitment of leucocytes and exacerbating the cytokine storm, effectively creating a self-perpetuating feedback loop that drugs targeting singular cytokines, such as TNF-α or IL-6, fail to fully quench.

Furthermore, the standard pharmacological approach often overlooks the dysregulation of the Cholinergic Anti-inflammatory Pathway (CAP). Research published in journals such as *The Lancet* and *Nature Reviews Rheumatology* highlights that the vagus nerve acts as a critical biological conduit, where efferent signals trigger the release of acetylcholine (ACh). This ACh binds to the alpha-7 nicotinic acetylcholine receptor (α7nAChR) on macrophages, inhibiting the production of pro-inflammatory cytokines. In RA patients, this neural 'brake' is frequently compromised. The systemic failure of this 'inflammatory reflex' means that even with intensive immunosuppression, the underlying autonomic imbalance continues to drive systemic inflammation.

Crucially, the mainstream narrative fails to address the 'centralisation' of RA, where chronic peripheral inflammation leads to the priming of microglia within the Central Nervous System (CNS). Once these glial cells are shifted into a pro-inflammatory M1 phenotype, they continue to emit neurotoxic cytokines long after joint-level inflammation has been pharmacologically managed. This explains the clinical paradox observed in UK rheumatology clinics: patients achieving 'remission' on paper (low DAS28 scores) who nevertheless suffer from debilitating fatigue and neuropathic pain. By ignoring the retrograde axonal transport of cytokines and the subsequent breakdown of the blood-brain barrier (BBB) integrity in RA, the current medical model treats the joint while leaving the neural circuitry of the disease intact. True therapeutic resolution requires an INNERSTANDIN of how the nervous system hard-wires the chronicity of the immune response, moving beyond mere molecular blockade toward the restoration of autonomic and neuro-immune homeostasis.

The UK Context

In the United Kingdom, the clinical landscape of Rheumatoid Arthritis (RA) is undergoing a radical conceptual transformation, moving beyond the traditional synovial-centric model towards a sophisticated appreciation of the neuro-immune axis. Currently affecting approximately 450,000 individuals across the British Isles, RA represents a profound burden on the National Health Service (NHS), yet contemporary research emerging from institutions like the Kennedy Institute of Rheumatology at the University of Oxford suggests that our pharmacological interventions have historically ignored the bidirectional signalling between the central nervous system (CNS) and the immune repertoire. At INNERSTANDIN, we recognise that the UK’s distinct patient cohorts provide a critical lens through which to observe how systemic inflammation, driven by pro-inflammatory cytokines such as Tumour Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6), does not merely result in joint erosion but actively reconfigures neural architecture.

The bidirectional path is most evident in the phenomenon of central sensitisation, which remains a primary driver of the 'pain gap' observed in NHS rheumatology clinics—where patients report debilitating pain despite achieving clinical remission according to Disease Activity Score-28 (DAS28) metrics. British longitudinal studies, frequently cited in *The Lancet Rheumatology*, highlight that the persistent elevation of circulating cytokines facilitates the breakdown of the blood-brain barrier’s functional integrity. This allows for the infiltration of myeloid cells and the activation of microglia within the dorsal horn of the spinal cord. Once activated, these microglia release further neuro-inflammatory mediators, creating a self-perpetuating feedback loop where the neural system becomes both a victim and a secondary source of inflammatory stimulus.

Furthermore, the UK’s pioneering work in bioelectronic medicine—specifically regarding the Vagus Nerve—has exposed the mechanisms of the Cholinergic Anti-inflammatory Pathway (CAP). Research conducted within the UK’s academic corridors suggests that the efferent vagal signal, which typically inhibits cytokine production via the alpha-7 nicotinic acetylcholine receptor (α7nAChR) on macrophages, is significantly attenuated in British RA patients. This neuro-immune 'silencing' suggests that RA is as much a neurological failure of homeostasis as it is an immunological aberration. By focusing on this crosstalk, INNERSTANDIN aims to highlight the necessity of integrated therapeutic frameworks that address the HPA-axis dysregulation and sympathetic nervous system overactivity prevalent in the UK population. The truth, often obscured by singular focus on JAK inhibitors or monoclonal antibodies, is that the resolution of RA requires the recalibration of the neural signals that dictate the intensity and duration of the immune response itself.

Protective Measures and Recovery Protocols

To mitigate the deleterious feedback loops inherent in the neuro-immune axis of Rheumatoid Arthritis (RA), recovery protocols must transcend conventional peripheral immunosuppression, targeting instead the bidirectional signalling pathways between the central nervous system (CNS) and the synovial microenvironment. At the vanguard of these protective measures is the modulation of the ‘Inflammatory Reflex,’ a biological mechanism mediated by the vagus nerve. Evidence published in *The Lancet* and various *PubMed*-indexed studies suggests that bioelectronic intervention—specifically Vagus Nerve Stimulation (VNS)—can significantly attenuate systemic TNF-α levels. By activating the cholinergic anti-inflammatory pathway (CAP), VNS triggers the release of acetylcholine, which binds to α7 nicotinic acetylcholine receptors (α7nAChR) on synovial macrophages. This molecular interaction inhibits the nuclear translocation of NF-κB, effectively silencing the transcription of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) before they can exacerbate nociceptive sensitisation. For the INNERSTANDIN researcher, this represents a shift from reactive pharmacology to proactive neuro-modulation.

A comprehensive recovery protocol must also address the phenomenon of ‘central sensitisation,’ where persistent cytokine-induced nociceptive barrage leads to functional and structural alterations in the dorsal horn of the spinal cord and higher cortical structures. To protect the neural architecture from this neuro-inflammatory erosion, the use of Small Molecule Inhibitors, specifically JAK (Janus Kinase) inhibitors, has shown promise not only in reducing joint erosions but in modulating the cytokine-driven ‘sickness behaviour’ and hyperalgesia mediated by the JAK-STAT pathway within microglia. British clinical guidelines are increasingly recognising that achieving clinical remission (DAS28 < 2.6) does not always equate to the cessation of neurogenic pain, necessitating the integration of N-methyl-D-aspartate (NMDA) receptor antagonists or glial cell modulators to ‘reset’ the neural threshold.

Furthermore, chronotherapeutic strategies are essential for synchronising therapeutic delivery with the circadian rhythm of cytokine production. In the UK context, research into the hypothalamic-pituitary-adrenal (HPA) axis dysfunction in RA patients reveals a nocturnal peak in IL-6. Protective measures should therefore include the administration of modified-release glucocorticoids or targeted biologics timed to intercept this early-morning cytokine surge, thereby preventing the morning stiffness and neural priming that characterises the disease.

Finally, recovery must leverage the biochemistry of resolution. The induction of Specialized Pro-resolving Mediators (SPMs), such as resolvins and protectins, offers a non-immunosuppressive route to actively terminate inflammation. Unlike traditional NSAIDs which merely inhibit cyclooxygenase enzymes, SPMs promote the phagocytosis of apoptotic neutrophils and the shift of macrophages from a pro-inflammatory M1 phenotype to a pro-resolving M2 phenotype. This metabolic "switch" is critical for the INNERSTANDIN objective of systemic restoration, ensuring that the neuro-immune crosstalk is not merely silenced, but re-tuned toward homeostasis and tissue repair. High-dose, pharmaceutical-grade Omega-3 fatty acids, serving as precursors to these SPMs, constitute a foundational nutritional-pharmacological protocol for long-term neuro-immunological stability.

Summary: Key Takeaways

The pathophysiology of Rheumatoid Arthritis (RA) transcends simple articular degradation, manifesting as a sophisticated neuro-immunological dysregulation where nociceptive signalling and cytokine cascades form a reciprocal, self-perpetuating loop. Evidence synthesised from *The Lancet* and *Nature Reviews Rheumatology* underscores that pro-inflammatory cytokines, specifically TNF-α, IL-6, and IL-1β, do not merely act as markers of synovial inflammation but function as potent neuromodulators. These molecules facilitate peripheral sensitisation by lowering the activation threshold of transient receptor potential (TRP) channels on primary afferent fibres. Crucially, the INNERSTANDIN perspective reveals that chronic systemic inflammation triggers microglial activation within the central nervous system, driving central sensitisation and the maladaptive "structural remodelling" of pain processing centres in the brain and spinal cord.

This bidirectional crosstalk is further mediated by the cholinergic anti-inflammatory pathway; vagus nerve dysfunction often precedes clinical synovitis, suggesting that neural "gating" of the immune response is a primary failure point in RA aetiology. Peer-reviewed data indicates that the persistent neurogenic inflammation observed in RA patients can remain refractory to traditional DMARD therapy if the neural component of the feedback loop is ignored. Ultimately, RA must be reconceptualised as a systemic failure of the neuro-immune rheostat, where the neural-glial-cytokine axis dictates both the severity of erosive progression and the intractable nature of the associated pain state. Research-grade insights demand that clinicians move beyond the joint to address the neuro-immune interface as the definitive site of pathology.